NICE approves Imbruvica for second-line leukaemia treatment
January 26, 2017Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica
NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …
Two infants in remission from leukaemia after CAR T-Cell therapy
January 26, 2017Research and Development
Researchers at the Great Ormond Street Hospital have published the successful treatment of two infants suffering from leukaemia by treatment …
India’s NPPA slashes essential drug prices by up to 50%
January 26, 2017Sales and Marketing India, nppa, pricing
India’s governmental regulatory agency, the National Pharmaceutical Pricing Authority (NPPA), has addressed the pricing of 33 medicines including antibiotics and …
Jazz Pharmaceuticals UK supplier hit with FDA warning
January 26, 2017Manufacturing and Production Erwinaze, Porton Biopharma, jazz pharmaceuticals
UK-based Porton Biopharma, supplier of Irish company Jazz Pharmaceuticals’ leukaemia treatment Erwinaze, has been slapped with an FDA warning letter …
J&J finally seals $30 billion deal for Actelion
January 26, 2017Sales and Marketing Actelion, Janssen, Johnson & Johnson
Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …
Regeneron agrees ownership of HQ for $720m after 25 years
January 25, 2017Manufacturing and Production, Medical Communications Regeneron
After leasing the property for 25 years, Regeneron has agreed to take ownership of its headquarters and buy the Landmark …
Hospira in US-wide recall of product due to contamination
January 25, 2017Medical Communications Contamination, Hospira, Pfizer
Hospira, a company owned by Pfizer, has been forced to recall a batch of injectable drugs due to “the presence …
Takeda UK names new market access director
January 25, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda
Takeda UK has appointed Peter Wheatley Price to the role of market access director, where he will also sit on …
MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme
January 25, 2017Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq
Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …
Statins revealed to potentially aid cancer treatment
January 25, 2017Research and Development Cancer, University of Kansan, statins
New research, conducted at the University of Kansas, has emerged that reveal a potential use for statins beyond their current …
Two-step treatment cuts off cancer’s backup defences
January 25, 2017Research and Development Cancer, sarcoma, washington university
New research conducted at Washington University’s School of Medicine and published in Cell Reports details a new method for fighting …
Breakthrough treatment for pancreatic cancer doubles survival rates
January 25, 2017Research and Development CRUK, Cancer Research UK, Pancreatic cancer
Research led by Liverpool University and funded by Cancer Research UK has shown that a combination treatment of two off-patent …
Indian pharma firm caught shredding documents at 1am by FDA
January 24, 2017Manufacturing and Production, Research and Development FDA, Hetero Labs, observations
Hetero Labs, an Indian pharmaceutical firm, has been observed by the FDA shredding what the FDA judged to be controlled …
Pharmafocus January/February is now live!
January 24, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, digital edition
Inside this issue…
EMA Accelerated Assessment for AbbVie’s hepatitis C regimen
January 24, 2017Manufacturing and Production, Research and Development AbbVie, EMA, hepatitis C
AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency …
US Pharma launches multi-million dollar media campaign to deflect pricing criticism
January 24, 2017Manufacturing and Production, Medical Communications PhMRA, Trump
In response to a number of recent criticisms over pricing including president Trump’s message that pharma companies are “getting away …
Roche’s Actemra granted Priority Review by FDA
January 24, 2017Manufacturing and Production, Sales and Marketing Actemra, FDA, Roche, priority review
Roche’s drug, Actemra (also known as RoActemra in Europe), has been granted priority review designation by the FDA for the …
Thinking big data
January 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Data, IBM Watson Health, ibm
The potential solutions offered by ‘big data’ seems to offer a vision of the future but potential solutions aren’t enough …
Rival to EpiPen to be made available to many for free
January 23, 2017Manufacturing and Production, Sales and Marketing Kaleo, Mylan, epipen, rival
Mylan has been under scrutiny over its pricing policy with its branded EpiPen; the pressure told and led to them …
CEPI backed by Bill Gates raises funds to combat epidemics
January 23, 2017Medical Communications, Sales and Marketing Bill & Melinda Gates foundation, Bill Gates, CEPI
CEPI, the Coalition for Epidemic Preparedness Innovations, have launched the beginning of its fundraising initiative – with the aim of …
